Endo, Inc. (OTCQX: NDOI) announced today that it has entered into a definitive agreement with MC2 Therapeutics ("MC2") to commercialize Wynzora® Cream (calcipotriene ...
Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.
One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.
According to a study published in Biomaterials Advances, scientists at the University of Copenhagen have developed a patch ...
Researchers have developed a patch for easier and more effective treatment of psoriasis. The method may also be used in treatment of other inflammatory skin diseases.
Researchers at the University of Copenhagen have developed a patch for easier and more effective treatment of psoriasis. The ...
If you have eczema you’ll be all too familiar with those cracked, dry, and scaly patches of skin that show up a bright red on ...
Q3 2024 Earnings Call Transcript November 7, 2024 Operator: Good day, and welcome to the Arcutis Biotherapeutics 2024 Third ...
Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...
Psoriasis is an autoimmune condition that can turn your skin red, and leave you with raised skin lesions, itching and burning ...